GUARNERI, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.964
EU - Europa 8.703
AS - Asia 8.539
SA - Sud America 1.263
AF - Africa 204
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 11
Totale 36.700
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.662
IT - Italia 2.574
SG - Singapore 2.573
CN - Cina 2.190
GB - Regno Unito 1.925
HK - Hong Kong 1.047
BR - Brasile 969
IE - Irlanda 863
VN - Vietnam 813
SE - Svezia 745
DE - Germania 620
BD - Bangladesh 518
FI - Finlandia 412
UA - Ucraina 397
RU - Federazione Russa 303
FR - Francia 282
TR - Turchia 246
KR - Corea 241
IN - India 232
CA - Canada 162
BG - Bulgaria 146
ID - Indonesia 135
AR - Argentina 95
NL - Olanda 93
JP - Giappone 79
MX - Messico 78
IQ - Iraq 69
ZA - Sudafrica 56
ES - Italia 54
PL - Polonia 54
AE - Emirati Arabi Uniti 45
PK - Pakistan 45
CO - Colombia 43
EC - Ecuador 40
PH - Filippine 39
LT - Lituania 33
CL - Cile 31
VE - Venezuela 31
MY - Malesia 29
BE - Belgio 28
UZ - Uzbekistan 28
AT - Austria 24
MA - Marocco 24
PY - Paraguay 24
SA - Arabia Saudita 24
EG - Egitto 23
IR - Iran 20
JO - Giordania 19
TW - Taiwan 19
CZ - Repubblica Ceca 17
HU - Ungheria 16
TH - Thailandia 16
AU - Australia 15
ET - Etiopia 15
GR - Grecia 15
KE - Kenya 15
AZ - Azerbaigian 14
CH - Svizzera 14
TN - Tunisia 14
DZ - Algeria 13
AL - Albania 12
BO - Bolivia 12
NG - Nigeria 12
PT - Portogallo 12
CR - Costa Rica 11
DO - Repubblica Dominicana 11
KZ - Kazakistan 11
OM - Oman 11
LB - Libano 10
RO - Romania 10
JM - Giamaica 9
NP - Nepal 9
RS - Serbia 8
SN - Senegal 8
UY - Uruguay 8
EU - Europa 7
HN - Honduras 7
IL - Israele 7
PA - Panama 7
QA - Qatar 7
CI - Costa d'Avorio 6
CY - Cipro 6
MD - Moldavia 6
PE - Perù 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
LV - Lettonia 5
MK - Macedonia 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
DK - Danimarca 4
KW - Kuwait 4
LA - Repubblica Popolare Democratica del Laos 4
AO - Angola 3
AP - ???statistics.table.value.countryCode.AP??? 3
BY - Bielorussia 3
KG - Kirghizistan 3
KH - Cambogia 3
MN - Mongolia 3
NO - Norvegia 3
Totale 36.642
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.750
Singapore 1.719
Ashburn 1.625
Fairfield 1.457
Southend 1.136
Woodbridge 1.094
Hong Kong 1.028
Chandler 916
Houston 888
Dublin 861
Jacksonville 736
San Jose 714
Dearborn 621
Ann Arbor 581
Seattle 548
Wilmington 516
Hefei 509
Beijing 504
Cambridge 483
Nyköping 434
London 381
Council Bluffs 349
Los Angeles 327
New York 289
The Dalles 278
Helsinki 266
Milan 256
Ho Chi Minh City 248
Modena 228
Chicago 223
Seoul 209
Hanoi 200
Rome 175
San Diego 163
Princeton 156
Sofia 139
Eugene 131
Lauterbourg 131
Izmir 126
Moscow 113
Buffalo 105
Jakarta 103
Munich 103
Salt Lake City 100
Dallas 96
Shanghai 96
São Paulo 84
Columbus 75
Naples 75
Bologna 59
Des Moines 58
Falls Church 57
Frankfurt am Main 57
Tokyo 53
Elk Grove Village 52
Orem 50
Turin 48
Boardman 47
Phoenix 45
Tampa 45
Da Nang 43
Florence 43
Toronto 42
Bari 41
Dong Ket 41
Atlanta 40
Norwalk 39
Bremen 37
Denver 37
Haiphong 37
Redwood City 35
Warsaw 34
Guangzhou 32
Fremont 31
Chennai 30
Palermo 30
Mexico City 28
Mumbai 28
Redondo Beach 28
Genoa 27
Rio de Janeiro 27
Turku 27
Nanjing 26
Brooklyn 25
Tashkent 25
Curitiba 24
Kunming 24
Miano 24
San Mateo 24
Amsterdam 23
Catania 23
Kent 23
Montreal 23
Nuremberg 23
Boston 22
Brussels 22
Ottawa 22
Stockholm 22
Verona 22
Johannesburg 21
Totale 25.091
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.158
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 491
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 430
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 428
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 412
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 384
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 382
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 379
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 373
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 371
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 371
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 368
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 354
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 352
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 351
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 340
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 336
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 334
Achievements and unmet needs in the management of advanced ovarian cancer 333
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience 325
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 320
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 316
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 314
Detection of microparticles from human red blood cells by multiparametric flow cytometry 313
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 312
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors 310
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 309
Immune characterization of breast cancer metastases: prognostic implications. 308
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 306
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 305
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 305
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 305
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 303
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 298
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 296
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 294
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 293
Trastuzumab containing regimens for early breast cancer. 285
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 283
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 273
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 272
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 267
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 263
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 263
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 261
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 260
Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer 259
Biomarkers predicting clinical benefit: fact or fiction? 258
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 258
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 257
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 252
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 252
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 250
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 249
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 249
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 247
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 245
Timing for starting second-line therapy in recurrent ovarian cancer 245
Biomarker expression and survival after primary chemotherapy for breast cancer. 245
The curability of breast cancer and the treatment of advanced disease 243
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 240
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 239
Bone metastases- Pharmacological treatment 238
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 237
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 236
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 234
Trastuzumab-containing regimens for metastatic breast cancer 233
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 233
Bevacizumab treatment for advanced breast cancer. 228
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 227
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 227
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 227
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 226
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer 226
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 226
Tumori ginecologici 225
Triple-negative breast cancer: current management and future options. 224
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 223
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 219
Pazopanib-Induced Heart Failure In A Metastastic Sarcoma Patient: Between Reversible Side Effect and Efficacy 219
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 219
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 217
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001 217
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 216
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 214
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer 213
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 210
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 210
In response to Jackson letter to the editor regarding "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens" 209
The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer 208
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 205
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 204
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. 202
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 200
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 200
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study 200
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation 200
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER 199
CARCINOMI MAMMARI HER2 POSITIVI: CASISTICA DI MODENA 199
Totale 28.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021157 0 0 0 0 0 0 0 0 0 0 0 157
2021/20222.363 61 280 288 108 64 135 149 119 278 202 394 285
2022/20233.462 331 307 174 248 282 375 52 248 1.156 48 137 104
2023/20242.185 98 131 120 134 324 172 169 437 75 115 161 249
2024/20256.106 185 117 106 483 1.214 1.089 323 387 673 314 488 727
2025/202612.582 705 405 882 1.326 1.982 838 1.514 646 1.136 1.243 1.075 830
Totale 36.939